InsiderPulse| Trade Date | Filed | Owner | Role | Type | Shares | Price | Value | Owned After | ||
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-05-06 | 2026-05-07 | Holzbaur Lynette | SVP and Corporate Controller | Purchase | 26.4K | $13.35 | $353K | 52.9K | View ↗ |
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenues | $6.22B-2.9% | $6.40B+2.2% | $6.26B+1.4% | $6.17B-2.1% | $6.30B |
| Cost of sales | $2.90B+8.0% | $2.69B+6.9% | $2.52B+9.6% | $2.29B-3.7% | $2.38B |
| Gross profit | $3.31B-10.8% | $3.71B-0.9% | $3.75B-3.4% | $3.88B | — |
| Selling, general and administrative | $1.72B-2.2% | $1.76B-7.0% | $1.89B+11.1% | $1.70B+2.2% | $1.67B |
| Research and development | $366.0M-22.0% | $469.0M-11.2% | $528.0M+12.1% | $471.0M+38.9% | $339.0M |
| Acquired in-process research and development and milestones | $6.0M-92.6% | $81.0M+912.5% | $8.0M-92.5% | $107.0M+2.9% | $104.0M |
| Goodwill impairment | $301.0M | $0 | $0 | — | — |
| Restructuring costs | $95.0M+206.5% | $31.0M-50.0% | $62.0M+121.4% | $28.0M+833.3% | $3.0M |
| Interest expense | $504.0M-3.1% | $520.0M-1.3% | $527.0M+24.9% | $422.0M+63.6% | $258.0M |
| Exchange losses | $14.0M-46.2% | $26.0M-38.1% | $42.0M+281.8% | $11.0M+175.0% | $4.0M |
| Other (income) expense, net | -$119.0M-666.7% | $21.0M+40.0% | $15.0M | — | — |
| Income before income taxes | $425.0M-47.3% | $807.0M+19.9% | $673.0M-40.0% | $1.12B | — |
| Income tax expense (benefit) | $238.0M+517.5% | -$57.0M+83.7% | -$350.0M | — | — |
| Net income | $187.0M-78.4% | $864.0M-15.5% | $1.02B+11.6% | $917.0M | — |
| Basic (in dollars per share) | $720K-78.6% | $3.4M-16.2% | $4.0M+11.1% | $3.6M | — |
| Diluted (in dollars per share) | $720K-78.4% | $3.3M-16.5% | $4.0M+11.1% | $3.6M | — |
| Basic (in shares) | $259.50B+1.0% | $257.05B+0.7% | $255.24B+0.5% | $254.08B+0.2% | $253.54B |
| Diluted (in shares) | $260.76B+0.6% | $259.15B+1.1% | $256.27B+0.4% | $255.17B+0.4% | $254.19B |
Source: SEC EDGAR XBRL. % change vs prior period shown where available.
Insider trades: Intel, Bank of America, and Pinterest among notable names
Organon Buyout By Sun Pharma Shifts Focus To Cash Value And Timing
Lilly, Gilead lead pharma’s M&A boom
Here are the major earnings before the open Thursday